Abstract
Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Current Drug Metabolism
Title: The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Volume: 9 Issue: 8
Author(s): M. N. Jacobs, W. Janssens, U. Bernauer, E. Brandon, S. Coecke, R. Combes, P. Edwards, A. Freidig, A. Freyberger, R. Kolanczyk, C. Mc Ardle, O. Mekenyan, P. Schmieder, T. Schrader, M. Takeyoshi and B. van der Burg
Affiliation:
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Abstract: Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Export Options
About this article
Cite this article as:
Jacobs N. M., Janssens W., Bernauer U., Brandon E., Coecke S., Combes R., Edwards P., Freidig A., Freyberger A., Kolanczyk R., Mc Ardle C., Mekenyan O., Schmieder P., Schrader T., Takeyoshi M. and Burg van der B., The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors, Current Drug Metabolism 2008; 9 (8) . https://dx.doi.org/10.2174/138920008786049294
DOI https://dx.doi.org/10.2174/138920008786049294 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells
Current Pharmaceutical Design Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer <i>via Salmonella</i> VNP20009
Anti-Cancer Agents in Medicinal Chemistry Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Nanotechnology as a Promising Strategy for Anticancer Drug Delivery
Current Drug Delivery Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry MicroRNAs as Therapeutic Targets for Anticancer Drugs in Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Regulation of the Metabolism of Polyunsaturated Fatty Acids and Butyrate in Colon Cancer Cells
Current Pharmaceutical Biotechnology Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry Dendrimers and the Development of New Complex Nanomaterials for Biomedical Applications
Current Medicinal Chemistry GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents The Effect of Krill Oil and n-3 Polyunsaturated Fatty Acids on Human Osteosarcoma Cell Proliferation and Migration
Current Drug Targets Local Physiological Regulation and Modern Treatments in Gynaecology
Current Women`s Health Reviews Structure-Based Approach for the Discovery of Novel Selective Estrogen Receptor Modulators
Current Medicinal Chemistry Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Biodistribution of Lipid Nanoparticles: A Comparative Study of Pulmonary versus Intravenous Administration in Rats
Current Radiopharmaceuticals Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery